Two multivalent foot-and-mouth disease inactivated vaccines containing South Africa Type 1 from Inner Mongolia Biwei Antai Biotechnology, a controlled subsidiary of Ruipu Bio, have been approved for production. The two vaccines are the bovine and ovine foot-and-mouth disease type O, type A, and South Africa Type 1 trivalent inactivated vaccine, known as Ruifeijing, and the porcine foot-and-mouth disease type O and South Africa Type 1 bivalent inactivated vaccine, known as Ruifeitai. The approval numbers are valid until July 19, 2028, precisely covering the three core livestock categories of pigs, cattle, and sheep. These two vaccines are the result of industry-academia-research collaboration between Ruipu Bio, the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, and the China Animal Disease Prevention and Control Center. Leveraging a five-stage purification process, the antigen purity can exceed 90 percent, offering the core advantage of one shot providing triple protection, reducing frequency and enhancing efficiency. They can simultaneously prevent multiple mainstream foot-and-mouth disease strains, greatly simplifying epidemic prevention procedures and lowering farming epidemic prevention costs.
Tianjin Ringpu Bio TechTwo new multivalent FMD vaccines approved for production, developed via industry-academia collaboration, offering improved efficacy and cost reduction.
As the controlled subsidiary that produced the approved vaccines, this directly benefits from the production approval.